Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Bologna – page 52

885 clinical trials in Bologna, Italy across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bologna at a glance
885
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

885 trials in Bologna

Open in trial search

Acne

Not recruiting

Title: Long-term safety study of N-Acetyl-GED-0507-34-LEVO gel 5% applied to the skin for patients with acne vulgaris

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:(S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid
  • Sponsor:PPM Services S.A.

Insomnia

Not recruiting

Study to Determine Safe and Effective Dose of Daridorexant for Treating Insomnia in Children and Adolescents Aged 10 to 18 Years

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Daridorexant
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Richter's syndrome

Not recruiting

Study on the Safety and Effectiveness of Venetoclax, Atezolizumab, and Obinutuzumab for Patients with Richter Syndrome from Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:ASST Grande Ospedale Metropolitano Niguarda

Triple negative breast cancer

Not recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Triple negative breast cancer

Not recruiting

Study Comparing Sacituzumab Govitecan to Physician's Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Breast cancer

Not recruiting

Study on Palbociclib and Drug Combination for Patients with Hormone Receptor Positive, HER2-Positive Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Alliance Foundation Trials LLC

Follicular lymphoma

Not recruiting

Study on Mosunetuzumab and Lenalidomide for Patients with Follicular Lymphoma After Previous Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Glomerulonephritis membranoproliferative+1

Not recruiting

Study on the Effectiveness and Safety of Pegcetacoplan for Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Malignant peritoneal neoplasm+2

Not recruiting

Study of Pembrolizumab for Patients with Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Dermatomyositis

Not recruiting

Study on the Safety and Efficacy of Empasiprubart for Adults with Dermatomyositis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Polycystic ovarian syndrome

Not recruiting

Study on the Effects of Spironolactone, Pioglitazone, and Metformin for Adolescent Girls and Young Women with Polycystic Ovary Syndrome (PCOS)

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Metformin
  • Sponsor:Fundacio Sant Joan De Deu

Ovarian low malignant potential tumour

Not recruiting

Study of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Catequentinib Dihydrochloride
  • Sponsor:Advenchen Laboratories LLC

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Bologna

What the registry says about research in the country

01 Hematological Disorders

Innovative research focusing on Immune Thrombocytopenia and various forms of blood cancers including Acute Myeloid Leukemia and Multiple Myeloma. These trials aim to evaluate novel therapeutic approaches and combination treatments.

  • Blood Disorders
  • Leukemia Research
  • Immunology Studies

Studies include evaluation of new compounds and their safety profiles in treating various blood-related conditions.

02 Gastrointestinal Research

Comprehensive studies on inflammatory bowel conditions, focusing on Crohn's Disease and Ulcerative Colitis. Research aims to develop more effective treatments for patients with moderate to severe disease activity.

  • Inflammatory Bowel Disease
  • Treatment Response
  • Disease Management

Trials evaluate both induction therapy and long-term treatment options for gastrointestinal conditions.

03 Neurological Conditions

Investigation of treatments for sleep disorders including Narcolepsy and Idiopathic Hypersomnia, along with research into Chronic Inflammatory Demyelinating Polyneuropathy.

  • Sleep Disorders
  • Neurological Diseases
  • Treatment Safety

Focus on developing safer and more effective therapies for various neurological conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.